SCHEMBL5136173

SCHEMBL5136173

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(CCC)Cc1ccc(C)cc1

nearest known ligand 0.47

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.47
TSHR P16473 4/20 0.44
CRHR1 P34998 4/20 0.39
TP53 P04637 1/20 0.39
HSD11B1 P28845 2/20 0.38
KDM4E B2RXH2 3/20 0.38
ALDH1A1 P00352 3/20 0.38
HPGD P15428 3/20 0.38
HSD17B10 Q99714 3/20 0.38
CYP3A4 P08684 2/20 0.38
NR1H3 Q13133 1/20 0.38
HRH3 Q9Y5N1 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5070130 0.96 C5AR1 (0.47) C5AR1TSHRCRHR1TP53HSD11B1
SCHEMBL5135570 0.94 C5AR1 (0.48) C5AR1TSHRCRHR1HSD11B1KDM4E
SCHEMBL5138025 0.94 C5AR1 (0.47) C5AR1TSHRCRHR1KDM4EALDH1A1
SCHEMBL5135106 0.94 C5AR1 (0.47) C5AR1TSHRCRHR1HSD11B1KDM4E
SCHEMBL5073888 0.93 C5AR1 (0.48) C5AR1TSHRCRHR1TP53HSD11B1
SCHEMBL5135643 0.92 C5AR1 (0.48) C5AR1TSHRTP53HSD11B1KDM4E
SCHEMBL5136220 0.92 C5AR1 (0.46) C5AR1TSHRCRHR1HSD11B1KDM4E
SCHEMBL5136560 0.92 C5AR1 (0.46) C5AR1TSHRCRHR1KDM4EALDH1A1
SCHEMBL5135043 0.92 C5AR1 (0.46) C5AR1TSHRCRHR1HSD11B1KDM4E
SCHEMBL5135599 0.91 C5AR1 (0.43) C5AR1TSHRCRHR1TP53HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed